Successful year for Galenika
The new business strategy of the domestic pharmaceutical company Galenika a.d. Belgrade, resulted in a significant increase in market share in domestic and foreign markets, expansion of the portfolio and increased production in 2019. Galenika achieved a significant shift from fourth to second place in terms of market share in Serbia, the portfolio for 8 products was expanded, and the production of its own product range increased by 32% compared to 2018.
In 2020, Galenika will be the holder of licenses for its products in the EU for the first time. The registration of the second product in the EU has been successfully completed and the registration process for an additional 3 new products is in progress. In addition to 39% growth in sales in the region (Montenegro, Bosnia and Herzegovina, Northern Macedonia), sales in international markets outside the region have been doubled compared to contracted deals over 2018. Sales in international markets outside the region are expected to double size in 2020. For more information please visit: https://bit.ly/2se5fEC